Acronym | Study name | Participants | Country | Number recruited | Tests/exposures | Outcome |
---|---|---|---|---|---|---|
PRIPS57 | Prospective validation of risk factors for the development of Parkinson syndromes | Subjects over 50 years old | Germany, Austria | 1847 | TCS, smell, UPDRS | Clinical diagnosis of PD |
TREND58 | Tübinger evaluation of risk factors for the early detection of neurodegeneration | Subjects over 50 years with anosmia, self-report RBD or depression | Germany | >1200 | TCS, smell, UPDRS, quantitative motor, psychometry, blood biomarkers | Clinical diagnosis of PD |
PARS43 | Parkinson's at-risk syndrom study | Subjects over 50 years with hyposmia and DaT deficit on SPECT | USA | 4999 (completed baseline smell test) | Smell, DaT SPECT, UPDRS, cognition, blood biomarkers | Clinical diagnosis of PD/DaT deficit on SPECT |
P-PPMI41 | Prodromal Parkinson's Progression Markers Initiative | Subjects with prodromal features or gene mutations | International | Anosmia/RBD=65 Genetic=150 | CSF and blood biomarkers, UPDRS, cognition, sleep and autonomic assessments | Clinical diagnosis of PD |
OPDC59 | Oxford Parkinson's Disease Centre study | Subjects with a first-degree relative with PD, or subjects with RBD (PSG confirmed) | UK | ∼190 | UPDRS, non-motor assessments, blood and CSF biomarkers | Clinical diagnosis of PD |
PREDICT-PD60 | PREDICT-PD | Subjects over 60 years old | UK | 1323 | In all (online): risk scoring, smell, RBDSQ, quantitative motor (BRAIN test), genetics In extremes of risk: UPDRS, cognitive, TCS | Clinical diagnosis of PD/DaT deficit on SPECT |
BRAIN test, BRadykinesia Akinesia INcoordination test; B-SIT, Brief Smell Identification Test; CSF, Cerebrospinal Fluid; DaT, Dopamine Transporter; PD, Parkinson's disease; PSG, polysomnography; RBD, REM sleep Behaviour Disorder; RBDSQ, RBD Screening Questionnaire; SPECT, single photon emission computed tomography; TCS, Transcranial Sonography; UPDRS, Unified Parkinson's Disease Rating Scale.